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A report on the First International Symposium of the
Austrian Proteomics Platform, Seefeld, Austria, 26-29
January 2004.
The perfectly organized Austrian Proteomics Platform
meeting that took place in the beautiful environment of the
Austrian Alps heralded a major initiative of Austrian
researchers and science-politicians in launching a program
in proteomics. Many leading experts in functional proteomic
studies gave an excellent overview of state-of-the-art pro-
teomic studies that certainly encouraged the many young
scientists participating at the meeting. 
Bridging genomics and proteomics 
Ronald Davis (Stanford Genome Technology Center, USA)
presented a number of techniques for functional genomics,
genotyping of single-nucleotide polymorphisms (SNPs),
and detecting mutations. A particular focus of this work is
the detailed analysis of gene function in yeast, using the
complete set of gene-deletion mutants that is now available
for this organism. Jason Ptacek (Yale University, New
Haven, USA) described the systematic analysis of yeast pro-
teins in liquid as well as in protein-chip format. A major
part of this analysis deals with the systematic characteriza-
tion of protein kinases, as well as proteins serving as sub-
strates for protein kinases. 
H.L. compared the cell to a neural network that computes the
phenotype from the genotype, additionally taking the environ-
ment into account. He highlighted new functional genomics
and proteomics technologies and discussed the need for new
integrated types of database, such as the GenomeMatrix
database [http://www.genome-matrix.org/] of the German
Resource Center for Genome Research (RZPD), and for
computer models if we are to understand data from high-
throughput genomics/proteomics experiments. 
Advances in technology and data interpretation 
Most current studies of proteomes are based on mass spec-
trometry (MS). Efforts in improving four aspects of such
studies are key for a more comprehensive study of the
human proteome - which is based on about 30,000 genes
resulting in more than 1,000,000 protein species. The first
need is for improved accuracy and speed of mass detection;
the second is improved separation of complex (protein) mix-
tures; the third need is methods for computationally refining
the signals obtained; and the fourth is ways of integrating
the flood of results in intelligent databases. 
Barry Karger (Barnett Institute, Northeaster University,
Boston, USA) gave an overview of several current MS tech-
niques. He emphasized the complementarity between differ-
ent techniques. In a comparative study of 51 ribosomal
proteins, only 32 proteins were identified by both of the
favored current techniques - matrix-assisted laser desorp-
tion/ionization (MALDI) MS and electrospray ionisation
(ESI) MS - whereas 8 proteins were found only by ESI-MS
and 11 only by MALDI-MS. 
Major improvements in technology from 1996 to date are a
150-fold increase in speed, by enhanced instrumentation
and lasers with higher frequency. Current strategies of data
analysis focus on de-noising using matched filtration and
wavelet transformation for signal processing. Important
steps in using MS to investigate the proteomes of tumor
tissues are efficient methods of obtaining sample. Karger
presented an automated laser-capture microdissection
process that allows him to obtain about 10,000 cells, or 1-4
g of total protein, in one cup. Relative quantification using
16O/18O exchange methods during trypsination resulted inseveral differentially regulated proteins in a breast cancer
study. The high potential of Fourier-transformed ion
cyclotron resonance-MS (FTICR-MS) became reality in an
experiment in which 1 g protein from 10,000 cells was used
and 820 proteins were identified. New evaluation programs
are in progress for the high mass-accuracy data obtained by
FTICR-MS. Further improvements may be expected by
miniaturization of columns down to 20 m inner diameter
and flow rates in the range of 20-50 nl/min, reaching a
detection limit of 5-10 amol of peptide.
The need for improvements in data acquisition, data analysis
and data assembly was also discussed by John Yates III
(Scripps Research Institute, San Diego, USA), who in partic-
ular emphasized their importance for the analysis of
complex protein mixtures in quantitative shotgun pro-
teomics. Applying subtractive proteomics to nuclear
envelopes, Yates and colleagues identified many novel enve-
lope proteins that could be mapped to chromosomal regions
linked to a variety of dystrophies. Given that metabolic label-
ing is helpful in studying the dynamics of proteomes, Yates
reported progress towards metabolic labeling in tissue by
feeding 15N-labeled proteins to rats.
Isabel Feuerstein and Sandra Morandell gave a ‘young inves-
tigator talk’ jointly from the labs of Günther Bonn and Lukas
Huber (all from the University of Innsbruck, Austria). Feuer-
stein pointed out that phosphoproteomics is important,
since there are about 100,000 potential phosphorylation
sites in the cell’s proteome, but only 2,000 are currently
known. She presented IDA-Fe3+-cellulose, a newly devel-
oped cellulose sorbent based on immobilized imino-diazetic
acid (IDA) ion exchange beads, for enhanced enrichment of
phosphopeptides in immobilized metal affinity chromatog-
raphy (IMAC). Morandell used this novel material for phos-
phoproteomics of the mitogen-activated protein (MAP)
kinase signaling pathway. 
Proteomics and disease
Several speakers described promising proteomics efforts that
aim to identify new targets for the diagnosis or treatment of
disease. Annemarie Poustka (Deutsche Krebsforschungszen-
trum (DKFZ), Heidelberg, Germany) presented a program of
research that intends to understand the underlying princi-
ples of disease, especially tumor etiology and development.
Part of the program is the sub-classification of cancers using
gene-expression profiling, in order to find changes in gene
expression between cancer cells and normal tissue. The
project is based on arrays (chips) bearing 36,000 human
cDNA clones for hybridization, and tissue-specific chips. By
hierarchical clustering of genes expressed in kidney tumors,
Poustka showed that there is a significant association with
chromosomal aberrations for 10-20% of genes that are dif-
ferentially expressed in tumors. Among the identified targets
there was a significant upregulation of genes involved in
glycolysis, whereas the genes involved in gluconeogenesis
were downregulated. Genes showing clear expression differ-
ences in tumors are now being screened in high-throughput
functional assays, to identify their function within the cell
and in the hope of unraveling the network of molecular
processes in different tumors. 
Tom Conrads (National Cancer Institute, Frederick, USA)
and John Semmes (Eastern Virginia Medical School,
Norfolk, USA) spoke about cancer profiling using crude bio-
logical samples, such as serum. Conrads stressed the impor-
tance of translational cancer research, which can be applied
to real clinical conditions; he investigates whether patterns
of proteins or peptides in blood can be used for histopathol-
ogy. Pointing out the power of modern FTICR-MS tech-
niques he reported the first success with a controlled ovarian
cancer dataset, for which he can distinguish tumor from
control samples with 100% sensitivity and 100% specificity.
A similar study presented by Semmes uses serum-protein
fingerprinting in prostate cancer.
Denis Hochstrasser (Geneva University Hospital, Switzer-
land) argued that because of the proteome’s complexity it is
important to decide at which level to work, and that simplifi-
cation might be a good strategy for asking the relevant ques-
tions, especially for smaller labs. As an example,
Hochstrasser used the clinical situation for stroke patients.
Since the worst outcome of stroke is death, he used the dead
brain as a model and found fatty-acid-binding protein as a
new marker for stroke. Moreover, he could differentiate
between ischemic or hemorrhagic stroke using the
apolipoprotein C-III gene as a marker. In a technological
development, Hochstrasser described how a molecular
scanner can be used for scanning two-dimensional elec-
trophoresis gels for MS. In the same way, direct blotting of
proteins from cryostatic sections from brain results in dis-
covery of the position of proteins within the tissue. Absolute
prerequisites for proteomic investigations are optimal docu-
mentation, controls and appropriate data-tracking and
retrieval, so as to provide possibilities for data mining, for
which laboratory information management systems (LIMSs)
are required. 
A role for proteomics in studying infectious diseases was
presented by P.R.J. Subtractive analyses by two-dimensional
gel electrophoresis plus MS, and by isotope-coded affinity
tag liquid chromatography MS (ICAT-LC/MS), resulted in
identification of about 30% of Mycobacterium tuberculosis
predicted genes at the protein level, and led to vaccine candi-
dates with promising results in preclinical vaccination
experiments. A multiparameter selection of protein candi-
dates, combining data from electrophoresis, MS, immuno-
proteomics, prediction of T-cell epitopes and others, also
revealed vaccine candidates for Helicobacter pylori, which
again have been tested in a mouse model successfully. An
international proteome database, called Proteome 2D-PAGE
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now open for the scientific community. 
Hanno Langen (Roche Genetics, Basel, Switzerland) dis-
cussed proteomics in the pharmaceutical industry for the
purpose of discovering and validating new molecular drug
targets, which he named three-dimensional proteomics. In
Bacillus subtilis, 1,505 different proteins were identified by
peptide-mass fingerprinting and tandem MS experiments.
Quantification is also possible by MS matching (finding hits)
without isotope labeling. He also emphasized that in an
industrial environment, a LIMS is a prerequisite for pro-
teomics. 
Exploring proteomes and protein complexes 
According to Joel Vandekerckhove (Ghent University,
Belgium), the dynamic range of proteins in a human cell
ranges from one molecule to up to 1010 molecules per cell.
This fact, together with difficult chemistry and no obvious
amplification procedure (unlike nucleic acids), means that
proteomics is a much more difficult challenge than
genomics. Complementary methods are necessary to get
access to a representative part of a proteome. One available
method is combined fractional diagonal chromatography
(COFRADIC), a peptide isolation procedure based on diago-
nal electrophoresis and diagonal chromatography.
The problem of characterizing the genomes of organisms
with unsequenced genomes was addressed by Andrey
Shevchenko (Max Planck Institute for Molecular Cell Biology
and Genetics, Dresden, Germany). He pointed out that even
homologous proteins are difficult to identify. As an example
he gave human dihydrodiol dehydrogenase (DDH) and alli-
gator alcohol dehydrogenase (ADH), which share 75%
sequence identity but no identical peptide in MS. Possible
ways to overcome this problem are the use of multiple tags
in combination with better computer algorithms and the
return of de novo sequencing.
Mathias Dreger (Free University of Berlin, Germany) intro-
duced subcellular proteomics and stressed that the subcellu-
lar distribution of components is an important property of
the proteome. He gave examples for the analysis of the
nuclear envelope and the analysis of spinal cord synaptic
membrane proteins, which are important for pain research.
C.S. went one step further within subcellular organization
and emphasized the increasing importance of protein com-
plexes and macromolecular machines. He presented cryo-
electron microscopy as a promising technique for structural
proteomics of such complexes, and introduced the Ultra-
Structure Network in Berlin, which is in the early stages of
development, as a research initiative that aims to achieve
high-throughput analysis of macromolecular complexes by
MS and cryo-electron microscopy. Overall, the meeting was
a genuine success and a promising start for GENAU, the
Austrian functional genomics program, and especially its
proteomics component. 
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